**INTRODUCTION:** Ventricular assist devices (VAD) are implantable cardiac devices, providing ventricular support for patients awaiting heart transplant and for those ineligible for transplant but require permanent (destination) therapy. On average, a destination therapy patient will depend on a VAD for 4.4 years.^1^ An infected VAD poses a challenge as device removal may not be an option, and the patient may be too unstable for device exchange. Flap coverage is a potential treatment for infected or exposed devices by enabling wound healing and delivery of immune cells with its rich vasculature.^2--4^ We study the outcomes of flap coverage on infected and/or exposed ventricular assist devices.

**METHODS:** A retrospective chart review of infected VAD patients treated with flap from 1960--2016 at our institution was conducted. Data studied included infection type, flap harvested, and number and type of adjunct surgical procedures. Survival outcomes with flap coverage were also reviewed.

**RESULTS:** From a review of 351 VAD patients, 11 flaps were used in nine infected VAD patients. There were seven males, and two females with an average age of VAD implant, and age of flap done at 55 ± 9.21 years, and 56.7 ± 9.4 years. Seven were destination therapy patients, and two were awaiting transplant. The most common infection was MRSA (n=4), and sites included driveline (4), pump pocket (5), and sternal wound (6). Flaps used were omentum (n=5), rectus abdominis (n=4), anterolateral thigh (n=1) and pectoralis major (n=1). Complications included abdominal wall hematoma after rectus flap, and omental flap necrosis. Additional procedures included debridement, VAC therapy, and incision and drainage. The average number of procedures to treat the infection was 3.7 ± 3.11. The average number of procedures before and after flap was 1.3 ± 0.86 (range 0--3), and 1.3 ± 2.34 (range 0--7). Seven of the nine patients expired, with a mean survival of 9.7 ± 5.3 months after flap, and 19.9 ± 13.7 months after initial VAD placement. Eight flap patients continued to suffer from a chronic VAD infection at time of death or last follow up, five of which expired from a septic cause. The two potential heart transplant recipients expired from sepsis prior to transplant.

**CONCLUSION:** Despite flap coverage, sepsis remains the lead cause of mortality in infected VAD patients.
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